V1 receptor Inhibitors
3 drugsAbout V1 receptor
The V1 receptor, also known as vasopressin receptor 1A (AVPR1A), is a G protein-coupled receptor that binds vasopressin, regulating blood pressure and fluid balance. It influences social behaviors through downstream signaling.
Genetic evidence offers moderate support for AVPR1A as a therapeutic target, with a max score of 0.31. Associations include frozen shoulder and glomerulonephritis (score 0.31).
Three FDA-approved small molecule drugs target the V1 receptor, including VASOPRESSIN. These drugs are marketed by Dr. Reddy's, Baxter, and GLAND.
V1 receptor Genetic Evidence Moderate
Genetic evidence shows moderate support for AVPR1A, with a max score of 0.31.
Further research is needed to validate AVPR1A as a drug target, given the moderate genetic support.
Evidence Across Diseases
5 totalGWAS and other genetic studies link AVPR1A to 5 diseases.
🔗 Colocalization Evidence 18 strong
max H4: 0.99eQTL/pQTL signals for AVPR1A colocalize with these GWAS traits, providing causal evidence that gene expression changes drive disease risk.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top V1 receptor Drugs
The competitive landscape includes Dr. Reddy's, Baxter, and GLAND, each with approved drugs.
The presence of only 3 companies suggests a relatively unconcentrated market with potential entry opportunities.
V1 receptor Drug Modality Landscape
Modalities
Routes of Administration
V1 receptor is druggable by small molecules, though no oral formulations are currently approved.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage.
V1 receptor Clinical Trials 144 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on V1 receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 17 | 11 | 3 | 3 | 79% |
| Phase 2 | 44 | 25 | 10 | 9 | 71% |
| Phase 3 | 31 | 17 | 3 | 11 | 85% |
| Phase 4 | 52 | 30 | 7 | 14 | 81% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
V1 receptor Drug Approval Timeline (2020 - 2024)
The first drug was approved in 2020, with the most recent approval in 2024.
The recent approval suggests continued interest in the target, but further approvals may saturate the market.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 120 (13 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on V1 receptor. A trial counts if an approved drug acting on V1 receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.